Manikanda Arunachalam

Manikanda Arunachalam is a San Francisco-based investor associated with The Lotus Capital, writing $250K-plus checks at seed and Series A into medical devices and AI/ML in healthcare. The Lotus Capital affiliation indicates a structured investment platform, and the check size is large enough to lead or co-lead small early rounds rather than only participating as a signal investor. The explicit AI focus paired with medical devices is differentiating: it points to interest in AI-enabled imaging, procedural devices with embedded ML, surgical robotics with computer vision, and clinical decision support tools that integrate with hardware. The Bay Area base provides access to West Coast healthcare investors, Stanford-Bayview-Mission Bay device and AI clinical relationships, and the broader San Francisco AI ecosystem. Founders most likely to fit are seed and Series A AI-enabled medical device companies, surgical and procedural AI platforms, imaging-AI tools with a hardware or workflow anchor, and any team where AI and device engineering converge with a clear regulatory pathway. Pure biotech, life sciences tools, consumer wellness, and pure SaaS without a device or AI-clinical wedge are weaker matches. The entry path is a LinkedIn message or a direct approach via The Lotus Capital, ideally warmed by a mutual Bay Area device or AI healthcare investor connection. Lead with the AI moat, the device or hardware integration story, the regulatory and clinical evidence plan, and the specific reason a Lotus-affiliated angel at $250K-plus materially accelerates the round and downstream Series B introductions.